Business Context and Reporting Period
Company: Deckers Outdoor Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1998
Business Overview: The Company designs, markets, and distributes outdoor footwear, primarily under the Teva(R), Simple(R), and Ugg(R) brands. Operations are highly seasonal, with Teva sales peaking in Q1/Q2, Simple in Q3, and Ugg in Q4.
Key Financial Metrics
| Metric | Three Months Ended June 30, 1998 |
Six Months Ended June 30, 1998 |
|---|---|---|
| Net Sales | $31,142,000 | $63,319,000 |
| Gross Profit | $12,922,000 (41.5% margin) | $26,459,000 (41.8% margin) |
| Net Earnings | $1,406,000 | $3,159,000 |
| Earnings Per Share (Diluted) | $0.16 | $0.36 |
| Cash Provided by Operating Activities | N/A | $3,603,000 |
| Cash and Cash Equivalents | $5,812,000 (as of June 30, 1998) | |
| Working Capital | $45,045,000 (as of June 30, 1998) | |
| Debt Obligations | Total Debt: $12,037,000 ($11,300,000 revolving credit facility + $737,000 long-term installments) |
Material Changes vs. Prior Period
- Revenue: Net sales increased 10.8% for the quarter and 1.2% for the six-month period compared to 1997. Teva(R) sales drove growth (up 23.9% Q/Q), while Simple(R) sales declined significantly (down 25.6% Q/Q).
- Profitability: Net earnings decreased 11.5% for the quarter and 11.7% for the six-month period. Gross margins compressed (from 44.6% to 41.5% Q/Q) due to increased inventory write-downs, closeouts, and airfreight costs.
- Expenses: Selling, general, and administrative (SG&A) expenses decreased as a percentage of sales due to the non-recurrence of 1997 litigation costs and reduced bad debt expense, partially offset by higher R&D and advertising spend.
- Interest: Net interest expense increased significantly (from $129,000 to $392,000 for the quarter) due to higher borrowings on the credit facility.
- Inventory: Inventory levels decreased 12.8% from year-end 1997 to June 30, 1998, reflecting normal seasonality.
Guidance, Outlook, and Risks
Management Outlook
- Q3 1998 Forecast: Management expects total sales to be significantly lower in Q3 1998 compared to the prior year. Simple(R) sales are expected to be significantly lower, while Teva(R) and Ugg(R) sales are expected to be flat to slightly down. The Company anticipates incurring a loss from operations and a net loss for the quarter.
- 1999 Prospects: Management remains optimistic about growth prospects for 1999 based on initial responses to Spring '99 lines.
Material Risks and Contingencies
- Product Recall: The Company intends to recall approximately 65,000 pairs of Spring 1998 Teva(R) infant sandals (approx. $800,000 in net sales) due to quality issues. The financial impact and recovery from the manufacturer are currently undetermined.
- Legal Proceedings: A 1995 lawsuit alleges trade secret infringement seeking $15 million in damages. The Company contests the claim and does not anticipate a material adverse effect.
- Trade Duties: The European Commission has enacted 49.2% anti-dumping duties on footwear from China/Indonesia. Dutch Customs opines that popular Teva styles may be covered. If confirmed, this could expose the Company to prior duties and force a change in sourcing or cessation of sales in Europe.
- Year 2000 Issue: The Company is assessing internal and third-party readiness for the Year 2000 computer issue but cannot yet determine the extent of exposure from suppliers or customers.
Investor Verification Checklist
- Verify the financial impact of the pending Teva(R) infant sandal recall and the likelihood of recovery from the independent factory.
- Monitor the resolution of the Dutch Customs anti-dumping duty dispute regarding Teva(R) styles and potential exposure to 1997 duties.
- Assess the severity of the anticipated Q3 1998 operating loss and its impact on full-year guidance.
- Review the status of the 1995 trade secret litigation and any potential settlement or judgment risks.
- Confirm the Company's ability to meet credit facility covenants, specifically the requirement to pay down the balance to under $2.5 million for 30 consecutive days in the upcoming 13-month periods.